Compare BlackRock TCP Capital Corp (TCPC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackRock TCP Capital Corp vs GeneDx Holdings Corp — how do they compare? BlackRock TCP Capital Corp trades at $3.24 (market cap $270.17M), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: GeneDx Holdings Corp is far larger — about 6.7× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 26.09% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| TCPC | WGS | |
|---|---|---|
Market Cap | $270.17M | $1.80B |
Sector | Financials | Technology |
52-Week High | $7.64 | $167.51 |
52-Week Low | $3.14 | $34.51 |
Dividend Yield | 26.09% | — |
Enterprise Value | — | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TCPC trades at $3.21, down 3.02% today, with a bearish technical signal from moving averages. The company reported negative revenue and net losses in 2025, though it beat Q1 2026 EPS estimates. A dividend of $0.17 per share is scheduled for June 30, 2026. Analyst consensus is mixed, with 31% buy ratings but 54% hold, reflecting caution amid financial challenges and an ongoing legal investigation into fiduciary duties.
The outlook remains cautious due to persistent negative earnings and revenue trends, with profitability metrics like ROE at -18.74% indicating weak shareholder returns. Risks include the shareholder lawsuit and competitive pressures in the BDC sector. Near-term focus is on the Q2 2026 earnings report due August 6, 2026, which could influence sentiment.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
